Treatment of mild to moderate Graves' ophthalmopathy with sodium diclofenac: a pilot study.

Related Articles

Treatment of mild to moderate Graves' ophthalmopathy with sodium diclofenac: a pilot study.

Arq Bras Endocrinol Metabol. 2011 Dec;55(9):692-5

Authors: Bloise W, Mimura LY, Moura J, Nicolau W

Abstract
OBJECTIVE: To report the use of sodium diclofenac, an antagonist of PPAR-gamma and cyclooxigenase-2 (COX-2) inhibitor in the treatment of mild to moderate Graves' ophthalmopathy.
SUBJECTS AND METHODS: Thirteen patients with clinical activity score (CAS) 2 to 7 were treated during a period ranging from 3 to 12 months (mean 7.8 � 3.4) with oral sodium diclofenac, 50 mg every 12 hours.
RESULTS: Extra-ocular muscle restriction and CAS improved significantly, p = 0.003 and = 0.004, respectively. Ocular pain and diplopia disappeared, except for one patient who reported improvement of these symptoms. No recurrence was found after interruption of treatment.
CONCLUSIONS: Treatment of moderate Graves' ophthalmopathy with oral sodium diclofenac is a good, safe and less expensive therapeutic option. Like others new treatment trials, findings must be confirmed in a greater number of patients in a controlled study.

PMID: 22231971 [PubMed - indexed for MEDLINE]

dovitinib dna-pk coxinhibitors